Therismos, one of the UK’s largest distributors of unlicensed medicines and subsidiary of leading European cannabis company, Cannaray Limited, today announced an exclusive partnership with Canopy Growth Corporation (“Canopy Growth”), a leading Global Cannabis Company.
Therismos has been appointed the sole distributor in the UK and Channel islands of Canopy Growth’s Spectrum Therapeutics medical cannabis products, to provide continued supply of these essential medicines to patients and healthcare professionals.
The partnership is expected to address the challenges of a complex regulatory landscape in the UK regarding cannabis products for medicinal purposes (CBPM). Therismos has established expertise in CBPM distribution through its existing networks and relationship to the wider Cannaray Limited Group, making them the ideal partner to ensure seamless supply of CBPM to patients in need.
“We are excited to partner with Therismos and Cannaray Limited, who have a strong reputation for delivering medical cannabis products and services to patients and healthcare professionals in the UK,” said Paul Steckler, Managing Director, International Markets, at Canopy Growth. “This partnership allows us to continue providing a seamless service and our high-quality Spectrum Therapeutics products to patients in the UK and Channel Islands via Therismos’ distribution networks.”
“We are delighted to partner with Canopy Growth and to have the opportunity to bring their range of Spectrum Therapeutics medical cannabis products to patients in the UK,” said Richard Lunney, Managing Director of Therismos. “Our expertise in distribution of medical cannabis products and other unlicensed medicines, combined with Canopy Growth’s commitment to patient access, makes this a powerful partnership.”
